Today: 9 July 2026
Synopsys stock today rises as tech slips, Dec. 30 lawsuit deadline nears
29 December 2025
2 mins read

Synopsys stock today rises as tech slips, Dec. 30 lawsuit deadline nears

NEW YORK, December 29, 2025, 15:46 ET — Regular session

  • Synopsys shares edged higher in afternoon trading, outperforming a softer tech session.
  • Law-firm notices flagged a Dec. 30 deadline tied to a proposed securities class action.
  • Traders are watching Fed minutes and jobless claims in a holiday-thinned week.

Synopsys, Inc. (SNPS) shares were up 0.4% at $479.18 in afternoon trading on Monday. The chip design software maker traded between $471.28 and $484.33.

The move stood out as the broader market drifted lower into year-end. SPY was down about 0.3%, while QQQ fell 0.4% and the semiconductor-focused SOXX slipped 0.3%.

Fresh legal headlines also put Synopsys back on some traders’ screens. Plaintiff law firm Bleichmar Fonti & Auld said in a notice that investors have until Dec. 30 to ask the court to appoint a lead plaintiff in a proposed securities class action.

Wall Street’s main indexes were lower on Monday as heavyweight technology shares pulled back from last week’s rally, a Reuters market report said. “This is (not) the beginning of the end of the tech dominance, it’ll turn out to be a buying opportunity,” said Hank Smith, director and head of investment strategy at Haverford Trust. Minutes from the Fed’s previous meeting and weekly jobless claims are the key data events in an otherwise quiet week, while U.S. markets are shut Thursday for New Year’s Day, the report said. Reuters

Cadence Design Systems, a close rival in electronic design automation, was down about 0.2%.

In a separate notice distributed via PR Newswire, The Gross Law Firm said the complaint alleges Synopsys and some executives made misleading statements tied to the economics of its Design IP business — pre-designed chip components sold to semiconductor customers — as more customization was required for some AI-related demand. The firm said the proposed class period runs from Dec. 4, 2024 to Sept. 9, 2025.

A lead plaintiff is typically the investor the court appoints to represent other shareholders and help direct the litigation. The role does not determine the merits of the allegations.

Synopsys has been volatile since September, when its shares slid nearly 35% in a session tied to concerns over its China business, Reuters reported at the time.

More recently, the company beat estimates for fiscal fourth-quarter revenue and forecast first-quarter revenue of $2.36 billion to $2.42 billion as customers kept spending on chip design and verification tools, Reuters reported. Synopsys competes with Cadence and Siemens in the electronic design automation market.

Synopsys also drew attention in December after Nvidia disclosed a $2 billion stake and a non-exclusive partnership aimed at speeding up simulations using Nvidia’s chips, Reuters reported.

Investors are also weighing Synopsys’ restructuring moves after it said in a regulatory filing in November it would cut about 10% of its workforce. The company completed its acquisition of engineering simulation software maker Ansys in July, an SEC filing showed.

For SNPS traders, the near-term focus is whether the shares can hold above the mid-$470s into year-end and whether the Dec. 30 lead-plaintiff deadline keeps the stock in the headlines. With liquidity thinning into the holiday, small shifts in risk appetite can move prices faster than usual.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors.

Stock Market Today

  • FTSE 100 slips as Middle East worries hit sentiment, AstraZeneca (LON:AZN) falls on drug miss
    July 9, 2026, 5:57 AM EDT. The FTSE 100 dropped 0.49% after new U.S. raids on Iranian targets and retaliatory drone attacks rattled markets. AstraZeneca shares were among the biggest losers, sliding after its Wainua heart drug didn't clear a key late-stage trial. Germany's DAX and France's CAC 40 ended firmer. Sterling rose against the dollar. Brent crude eased a bit as tensions stayed high, while gold moved up on safety buying. Computacenter traded higher. The IT group raised its outlook, pointing to strong trading and higher expected 2026 profits.
JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next
Previous Story

JNJ stock edges higher after Johnson & Johnson closes $3.05B Halda deal; earnings outlook next

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target
Next Story

Newmont stock rebounds as gold steadies after CME margin jolt; Raymond James lifts target

Go toTop